| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a80cbaaeee718664126e579cf4e41c2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 |
| filingDate |
2008-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0dbcc7f4b4d5333f54cf6c92b6eee7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15e1f93f8225a28f01368cfd5dd22240
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0170e968988c087246e3708e633c23a4 |
| publicationDate |
2017-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2709104-C |
| titleOfInvention |
Method and composition for treating a serotonin receptor-mediated condition |
| abstract |
The subject invention provides the use of a therapeutically effective amount of 4-[3-[4(6-fluoro-1,2,-benzisoxazol-3-yI)-1-piperidinyl]propoxy]-3-methoxy-benzoic acid or pharmaceutically-acceptable salt thereof (in a controlled or sustained release pharmaceutical dosage form) for antagonizing a 5-HT2A receptor in an animal suffering a condition that is mediated by a 5-HT2A receptor. |
| priorityDate |
2007-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |